4 Stocks Trending On Social Media This Wednesday
iSentium is a company that tracks sentiment on Twitter and enables users to sift through Tweets with ease. The application plots sentiment over a price chart and helps to identify changes that may impact pricing trends. Each morning, the firm generates a Pre-Market report for end-users. Benzinga uses the application and is republishing their morning note with iSentium's blessing.
American Express Company (NYSE: AXP) was upgraded this morning by Goldman Sachs research from neutral to buy, setting a price target of $102 for the financial services firm. Goldman Sachs cited improved market share and customer acquisition metrics, as well as reduced costs, in support of its bullish thesis. The upgrade generated consistently positive sentiment for American Express in the pre-market, with rising tweet volumes contributing to a bullish iSENSE alert at 8:05AM. The stock was up over 1 percent in early hours trading.
Eli Lilly and Co (NYSE: LLY) announced this morning a lowered outlook for sales in 2015 due to impending patent expirations, but the company revealed a new strategy focusing on growth in its diabetes and cancer product lines. The 2015 estimates came in below market consensus for the pharmaceutical manufacturer and retailer. Mixed sentiment on the news produced first positive then negative sentiment, with both bullish and bearish iSENSE alerts generated in pre-market trading. It was up 1.3 percent before market open.
Keurig Green Mountain Inc (NASDAQ: GMCR) reported this morning it had reached an agreement with Dr Pepper Snapple Group to produce single-serve packets for the group’s carbonated beverage line. The deal is Keurig’s largest development partnership since Coca-Cola, which was announced last year. Today’s sentiment reaction to the news was mixed but predominantly positive, with higher-than-usual tweet volumes generating a bullish iSENSE alert at 8:38AM. Green Mountain was up almost 3 percent in pre-market trading.
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported the Phase Ib clinical trials for its autoimmune drug APD334 had produced positive results, with a significant improvement in metrics for immune system functioning in a patient population. The drug had no serious side effects related to heart, lung, or liver function – a possible concern for the pharmaceutical firm. Arena announced plans to move forward quickly with Phase II testing. Despite the trial results this morning, sentiment for Arena remained negative and created a bearish iSENSE alert at 8:18AM. Arena was up close to 13 percent in pre-market trading.
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.